Details for New Drug Application (NDA): 065441
✉ Email this page to a colleague
NDA 065441 describes CEFEPIME HYDROCHLORIDE, which is a drug marketed by Acs Dobfar, Astral, Chartwell Rx, Hikma, Hospira Inc, Qilu, Sagent Pharms Inc, and Samson Medcl, and is included in nine NDAs. It is available from seven suppliers. Additional details are available on the CEFEPIME HYDROCHLORIDE profile page.
The generic ingredient in CEFEPIME HYDROCHLORIDE is cefepime hydrochloride. There are twenty drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.
The generic ingredient in CEFEPIME HYDROCHLORIDE is cefepime hydrochloride. There are twenty drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.
Summary for 065441
| Tradename: | CEFEPIME HYDROCHLORIDE |
| Applicant: | Acs Dobfar |
| Ingredient: | cefepime hydrochloride |
| Patents: | 0 |
Suppliers and Packaging for NDA: 065441
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 065441 | ANDA | Hospira, Inc. | 0409-9566 | 0409-9566-10 | 10 VIAL in 1 CARTON (0409-9566-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0409-9566-01) |
| CEFEPIME HYDROCHLORIDE | cefepime hydrochloride | INJECTABLE;INJECTION | 065441 | ANDA | Hospira, Inc. | 0409-9735 | 0409-9735-10 | 10 VIAL in 1 CARTON (0409-9735-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0409-9735-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Mar 20, 2008 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Mar 20, 2008 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
